Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.4 (
trypsin
)
42,187
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glandular kallikrein (a trypsin-like serine protease) is an estrogen-induced and dopamine-repressed protein in the rat anterior pituitary which appears to be associated with lactotrophs. This study examined
glandular kallikrein
levels in diethylstilbestrol (DES)-induced pituitary tumors in F344 rats and compared it to plasma and pituitary prolactin, and pituitary wet weight. Ovariectomized F344 rats were implanted with Silastic tubes containing 0 or 5 mg DES for 1, 3, 5, 7, or 9 weeks. Glandular kallikrein was measured by microenzymatic assay using D-valylleucylarginyl-p-nitroanilide following
trypsin
treatment of extracts to activate latent forms of
glandular kallikrein
. Prolactin was measured by radioimmunoassay. DES induced steady time-dependent increases in pituitary wet weight with 7- and 16-fold increases observed by 5 and 9 weeks, respectively. Growth rates averaged 11.4 mg/week during the first 5 weeks of DES exposure, and then increased to 23.2 mg/week between weeks 5 and 9. Glandular kallikrein total activity (nmol/min/pituitary) increased 130- and 240-fold after 3 and 5 weeks of DES exposure, respectively, and then abruptly plateaued. The specific activity (nmol/min/mg protein) of
glandular kallikrein
peaked at 3-5 weeks (36-fold increase compared to controls) and then declined as pituitary protein but not
glandular kallikrein
continued to increase. Total pituitary prolactin constantly rose during DES exposure with 12- and 26-fold increases after 5 and 9 weeks, respectively. Plasma prolactin levels also continuously rose during exposure to DES with 130- and 290-fold increases after 5 and 9 weeks, respectively. No major strain differences were found with regard to sensitivity to the acute effects of estrogen or dopaminergic stimulation on
glandular kallikrein
induction. DES-induced pituitary tumors in F344 rats are well known to arise via lactotroph proliferation, and the striking elevation in
glandular kallikrein
and prolactin during the early phases of tumor growth provide further support for a localization of
glandular kallikrein
in lactotrophs. However, the abrupt stabilization in
glandular kallikrein
levels by week 5 was unexpected and may signal a biochemical transformation of the tissue during tumor progression.
...
PMID:Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin. 339 Aug 8
The relationship between chemical modifications of arginine derivatives and inhibitory activity to horse serum cholinesterase (BuChE) was investigated. It provided a new insight into the topography of the active site of BuChE. 1) BuChE has the hydrophobic binding pocket, the depth of which corresponds to the length of ethylpiperidine. 2) In the opposite side to the hydrophobic binding pocket, BuChE has a certain entity which repulses carboxyl group at the 2-position of piperidine of L-arginine piperidine amide. 3) The P site of BuChE can allow 4-propyl and 4-phenyl group attached to piperidine. Comparison of the results with those of thrombin and
trypsin
clearly revealed similarities and dissimilarities among BuChE,
trypsin
, and thrombin in the active site topography, and hence, we introduce a new selective inhibitor for BuChE, N alpha-dansyl-L-arginine 4-phenylpiperidine amide. It inhibits BuChE strongly (Ki = 0.016 microM), whereas it inhibits
trypsin
, thrombin, plasmin, and
glandular kallikrein
only weakly and shows actually no inhibition on acetylcholinesterase from the human erythrocyte. In addition, the new inhibitor becomes highly fluorescent when bound with BuChE, indicating that the compound is an ideal probe of the interactions of BuChE as well as a titrant of it.
...
PMID:N alpha-dansyl-L-arginine 4-phenylpiperidine amide. A potent and selective inhibitor of horse serum cholinesterase. 340 26
This study examined whether the neurointermediate lobe (NIL) of the rat pituitary contains latent kallikrein- and thrombin-like proteases activated by
trypsin
. Partial characterization of such proteases was attempted. Also examined were the distribution of proteolytic activity within the NIL and levels in both male and female lobes. NIL homogenates were assayed for proteolytic activity at pH 8.0 before and after incubation with
trypsin
(10 micrograms/ml). Trypsin caused a 10-fold activation of kallikrein-like activity and a 40-fold activation of thrombin-like activity in NIL homogenates. The kallikrein-like activity was separated into two components using diethylaminoethyl-Sephadex. The predominant kallikrein-like protease was a potent kininogenase closely related or identical to
glandular kallikrein
and was almost exclusively localized to the intermediate lobe. The second kallikrein-like protease (kallikrein A) was a weak kininogenase sensitive to inhibition by both soybean trypsin inhibitor and aprotinin and was similarly concentrated in both the neural lobe and the intermediate lobe. The thrombin-like protease was sensitive to inhibition by hirudin (a specific thrombin inhibitor), clotted fibrinogen, and was slightly more concentrated in the neural lobe than in the intermediate lobe. NILs from female rats contained approximately 40% less kallikrein activity than NILs from male rats but did not differ in their content of thrombin-like activity.
...
PMID:Trypsin activation, partial characterization, and distribution of kallikrein-like and thrombin-like proteases in the neurointermediate lobe of the rat pituitary. 351 68
Discrepant reports exist regarding the presence of
glandular kallikrein
or other
trypsin
-like serine proteases in the pituitary. The existence of pituitary kallikreins in latent forms could explain these discrepancies. I report that
trypsin
treatment of rat anterior pituitary homogenates activates two serine proteases which generate kinins from kininogen and selectively cleave chromogenic substrates for kallikreins. One protease (enzymatically and immunologically resembling
glandular kallikrein
) and activated 5-fold by
trypsin
and was 20 times more abundant in female than in male lobes due to hormonal regulation by ovarian estrogens. The second kallikrein (activated 20-fold by
trypsin
) was unaffected by estrogens. The results demonstrate that rat anterior pituitary kallikreins predominantly exist in latent forms requiring activation for detection. Additionally,
glandular kallikrein
is a major estrogen-induced protein in the rat anterior pituitary. No other member of this large protease family is known to be regulated by estrogens.
...
PMID:Anterior pituitary glandular kallikrein: trypsin activation and estrogen regulation. 352 14
Homogenates of rat adipocytes and plasma membranes thereof were shown by radioimmunoassay to contain immunoreactive
glandular kallikrein
. On the basis of the hydrolysis of D-Val-Leu-Arg-p-nitroanilide, the kallikrein-like enzyme associated with the plasma membranes was found not to be stimulated by prior incubation with melittin or phospholipase A2. However, pre-incubation of the membrane preparation with
trypsin
did increase the activity of the enzyme. Furthermore, activation could also be achieved by incubating the plasma membranes with insulin at a dose that stimulated glucose uptake into intact adipocytes. On the other hand, incubation with insulin at a dose that did not increase glucose uptake into rat adipocytes was ineffective in activating the kallikrein-like enzyme.
...
PMID:Initial observations of a kallikrein-like enzyme associated with the plasma membranes of rat adipocytes. 354 19
The intermediate lobe of the rat pituitary contains a
trypsin
-like protease closely related or identical to
glandular kallikrein
. This study examined whether
glandular kallikrein
in the intermediate lobe is under inhibitory control by dopaminergic systems. Male rats were treated for 4-6 days with various doses of the following drugs, alone or in combination: haloperidol (a dopamine receptor blocker), reserpine (a catecholamine depleting agent), and bromocriptine (a dopamine receptor agonist). Neurointermediate lobe (NIL) homogenates were prepared. Following activation of latent enzymes with
trypsin
,
glandular kallikrein
was measured using two chromogenic peptide substrates. Haloperidol doubled NIL
glandular kallikrein
activity. Dissection of the NIL revealed that haloperidol specifically increased
glandular kallikrein
in the intermediate lobe and had no effect on the small amount of activity in the neural lobe. Reserpine also doubled NIL
glandular kallikrein
and haloperidol did not produce further increases. The reserpine-induced increase in NIL
glandular kallikrein
was completely blocked by concurrent administration of bromocriptine: this effect was blocked by haloperidol. The results demonstrate that intermediate lobe
glandular kallikrein
is under inhibitory control by dopaminergic systems. This parallels the regulation of proopiomelanocortin (POMC) synthesis in the intermediate lobe and suggests that
glandular kallikrein
should be evaluated as a POMC-processing enzyme.
...
PMID:Dopaminergic regulation of glandular kallikrein in the intermediate lobe of the rat pituitary. 363 74
A thiol proteinase inhibitor (TPI) has been purified from the ascitic fluid of Sarcoma 180 tumor-bearing mice. The molecular weight of the inhibitor was estimated to be 67,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the substance inhibited papain, cathepsins B and L, but not cathepsins H and D and
trypsin
. The inhibitor also liberated kinin upon treatment with
trypsin
or mouse
glandular kallikrein
, indicating that the inhibitor is a kininogen, and the kinin liberated upon trypsinization was identified as bradykinin. An immunoreactive TPI with a molecular weight indistinguishable from that of the ascites TPI was found in plasma of non-tumor-bearing mice as well as that of tumor bearers. Plasma levels of immunoreactivity were increased up to twice the normal levels in tumor bearers inoculated with Sarcoma 180 or 3LL tumor cells. Supplementation of the purified ascites TPI into Sarcoma 180 culture medium caused a significant suppression of cell growth as well as [3H]thymidine incorporation at a concentration below that normally present in plasma. In contrast, addition of ascites-TPI to cultured mouse embryonic cells caused enhancement of cell growth as well as [3H]thymidine incorporation. These results indicate that in mice responding to tumor growth, a TPI corresponding to a kininogen is induced which may regulate tumor growth by countering tumor-related proteolytic activity.
...
PMID:Thiol proteinase inhibitor in the ascitic fluid of sarcoma 180 tumor-bearing mice. 366 64
Glandular kallikrein (a trypsin-like serine protease) is a major estrogen-induced protein in the rat anterior pituitary, which appears to be associated with lactotropes. The present study examined
glandular kallikrein
levels in the anterior pituitary during the rat estrous cycle and pregnancy. After
trypsin
treatment of anterior pituitary homogenates (to activate latent forms of the enzyme),
glandular kallikrein
activity was measured by using the chromogenic substrate D-val-leu-arg-p-nitroanilide: 98-95% of the enzymatic activity was immunoprecipitable with
glandular kallikrein
antiserum. Glandular kallikrein levels did not change significantly during the various phases of the rat estrous cycle. However, a sharp decrease was observed starting on Day 15 of pregnancy and lasting through parturition; levels had almost returned to control values by Day 5 of lactation.
...
PMID:Glandular kallikrein levels in the rat anterior pituitary during the estrous cycle and pregnancy. 367 89
The effect of dopamine receptor blockers on
glandular kallikrein
-like activity in the neurointermediate lobe of the rat pituitary was examined. Male rats were given daily injections of haloperidol (2.5 mg/kg), perphenazine (5 mg/kg) or sulpiride (60 mg/kg) for 7 days. Homogenates of the neurointermediate lobe were prepared. Latent proteases were activated with
trypsin
and proteolytic activity was measured at 37 degrees C, pH 8.0 using chromogenic peptide substrates. All three dopamine receptor blockers produced about a 100% increase in
glandular kallikrein
-like activity. The results suggest that
glandular kallikrein
-like activity in the neurointermediate lobe is under inhibitory control by dopaminergic mechanisms.
...
PMID:Dopamine receptor blockade increases glandular kallikrein-like activity in the neurointermediate lobe of the rat pituitary. 388 13
Inactive renin-like enzyme(s) in the arterial wall of the rat are converted to active renin-like enzyme in vitro by either "acid activation" (dialysis to pH 3.3 followed by dialysis to pH 7.4) or "protease-induced activation" (
trypsin
, alpha-chymotrypsin and
glandular kallikrein
). The molecular weights of the inactive renin-like enzyme(s) before
trypsin
activation were estimated to be about 68,000, 44,000, 36,000 and 30,000 by column chromatography. These findings may offer a new aspect for the role of the arterial renin-angiotensin system in the local control of vascular tone by interconversion of the inactive to the active renin-like enzymes in the arterial wall.
...
PMID:Evidence for existence of inactive arterial renin-like enzyme in the rat. 388 57
<< Previous
1
2
3
4
5
6
7
8
Next >>